Allakos Inc. (ALLK)

NASDAQ: ALLK · Real-Time Price · USD
1.040
-0.040 (-3.70%)
At close: Dec 11, 2024, 4:00 PM
1.050
+0.010 (0.96%)
Pre-market: Dec 12, 2024, 6:40 AM EST
-3.70%
Market Cap 92.92M
Revenue (ttm) n/a
Net Income (ttm) -178.75M
Shares Out 89.34M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 229,525
Open 1.090
Previous Close 1.080
Day's Range 1.010 - 1.090
52-Week Range 0.540 - 3.410
Beta 0.91
Analysts Hold
Price Target 1.67 (+60.58%)
Earnings Date Nov 6, 2024

About ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 19, 2018
Employees 131
Stock Exchange NASDAQ
Ticker Symbol ALLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is $1.67, which is an increase of 60.58% from the latest price.

Price Target
$1.67
(60.58% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Allakos Runs Up Into A Near-Term Catalyst

Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006 demo...

5 weeks ago - Seeking Alpha

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...

5 weeks ago - GlobeNewsWire

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– ...

2 months ago - GlobeNewsWire

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...

4 months ago - GlobeNewsWire

The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

5 months ago - Accesswire

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

6 months ago - Accesswire

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy...

6 months ago - GlobeNewsWire

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Join

LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

6 months ago - Accesswire

The Schall Law Firm Starts Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate

LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

6 months ago - Accesswire

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Get Involved

LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

6 months ago - Accesswire

Claims Against Allakos Inc The Schall Law Firm Begins Probe And Urges Affected Investors To Participate

LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

6 months ago - Accesswire

Allegations Against Allakos Inc The Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved

LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

6 months ago - Accesswire

Claims Against Allakos Inc Schall Law Firm Begins Probe And Urges Affected Investors To Participate

LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

6 months ago - Accesswire

Allegations Against Allakos Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved

LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...

6 months ago - Accesswire

Charges Against Allakos Inc.: Schall Law Firm Launches Examination And Invites Affected Investors To Participate

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

Accusations Against Allakos Inc.: Schall Law Firm Begins Inquiry And Calls On Impacted Investors To Engage

LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

Claims Against Allakos Inc.: Schall Law Firm Initiates Probe And Invites Affected Investors To Connect

LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

Allegations Against Allakos Inc.: Schall Law Firm Begins Investigation And Encourages Impacted Investors To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

Allakos Inc. Allegations: Schall Law Firm Initiates Probe and Invites Affected Investors to Connect

LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

The Schall Law Firm is Initiating a Probe into Allegations Against Allakos Inc. and Invites Investors who have Suffered losses to Get in Touch

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

ALLK IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

6 months ago - Accesswire

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment ...

7 months ago - GlobeNewsWire

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...

7 months ago - Accesswire